S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Bank Accounts: Frozen! (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Bank Accounts: Frozen! (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Bank Accounts: Frozen! (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Bank Accounts: Frozen! (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Bank Accounts: Frozen! (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Bank Accounts: Frozen! (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Bank Accounts: Frozen! (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Bank Accounts: Frozen! (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
OTCMKTS:DCHPF

Dechra Pharmaceuticals - DCHPF Stock Forecast, Price & News

$31.35
0.00 (0.00%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$31.35
$31.35
50-Day Range
$31.35
$37.46
52-Week Range
$27.90
$42.75
Volume
N/A
Average Volume
843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DCHPF stock logo

About Dechra Pharmaceuticals (OTCMKTS:DCHPF) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DCHPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCHPF Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
See More Headlines
Receive DCHPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Pharmaceuticals - Other
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DCHPF
CIK
N/A
Fax
N/A
Employees
1,699
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Ian D. Page (Age 62)
    CEO, MD & Exec. Director
    Comp: $1.52M
  • Mr. Paul Nicholas Sandland MAAT (Age 44)
    FCCA, CFO & Exec. Director
    Comp: $952.39k
  • Dr. Anthony Gerard Griffin (Age 60)
    MD of Dechra Veterinary Products for Europe & Exec. Director
    Comp: $724.54k
  • Mr. Patrick Meeus
    Group Scientific Officer
  • Ms. Katy Clough
    Group HR Director
  • Mr. Mike Eldred (Age 53)
    Pres of North America
  • Ms. Melanie Hall
    Company Sec.













DCHPF Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCHPF shares.
View DCHPF analyst ratings
or view top-rated stocks.

How have DCHPF shares performed in 2023?

Dechra Pharmaceuticals' stock was trading at $32.2480 at the beginning of the year. Since then, DCHPF stock has decreased by 2.8% and is now trading at $31.3481.
View the best growth stocks for 2023 here
.

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the OTCMKTS under the ticker symbol "DCHPF."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DCHPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DCHPF stock can currently be purchased for approximately $31.35.

How many employees does Dechra Pharmaceuticals have?

The company employs 1,699 workers across the globe.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is Cheshire Business Park, Northwich, Cheshire CW9. The official website for the company is dechra.com. The company can be reached via phone at 44.16.0681.4730.

This page (OTCMKTS:DCHPF) was last updated on 4/1/2023 by MarketBeat.com Staff